TCM
MRNA icon

Triumph Capital Management’s Moderna MRNA Stock Holding History

Triumph Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7K Sell
100
-200
-67% -$10.3K ﹤0.01% 1256
2026
Q1 		$15.2K Hold
300
– – ﹤0.01% 973
2025
Q4 		$8.85K Buy
+300
New +$8.15K ﹤0.01% 1115
2022
Q3 		– Sell
-4,003
Closed -$572K – 218
2022
Q2 		$572K Sell
4,003
-17
-0.4% -$2.43K 0.3% 75
2022
Q1 		$692K Buy
+4,020
New +$677K 0.3% 80

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Triumph Capital Management's MRNA Position: Q2 2026 in Review

Triumph Capital Management reduced its Moderna (MRNA) stake by 67% in Q2 2026, selling an estimated $10.3K and leaving 100 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #1256.

Triumph Capital Management first reported a position in MRNA in Q1 2022 and has held it in 5 quarters since. The position peaked at $692K in Q1 2022. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Triumph Capital Management held 100 shares of Moderna worth $7K as of Q2 2026.
  • Triumph Capital Management sold 200 Moderna shares in Q2 2026, an estimated $10.3K.
  • Moderna made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1256 holding.
  • Triumph Capital Management first reported a position in Moderna in Q1 2022 and has held it in 5 quarters since.
  • Triumph Capital Management's Moderna position peaked at $692K in Q1 2022.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.